Fox Chase Cancer Center News

PHILADELPHIA (June 15, 2016) — June is National Cancer Survivorship Month. This month, Fox Chase Cancer Center physicians celebrate individuals who have overcome cancer while emphasizing the importance of staying healthy after completing cancer treatment.

PHILADELPHIA (May 25, 2016) — In a study of those patients with advanced non-squamous non-small cell lung cancer (NSCLC), those treated with the drug OPDIVO^® (nivolumab) demonstrated improved overall survival over patients treated with the drug Taxotere^® (docetaxel). 

PHILADELPHIA (May 24, 2016) — Researchers from Fox Chase Cancer Center – Temple Health have found that patients’ starting oral anticancer medications (OAM) can face delays in starting treatment due to the complexity of the processes needed to obtain these medications. These findings will be announced at The American Society of Clinical Oncology (ASCO) 2016 Annual Meeting.

PHILADELPHIA (May 23, 2016) —Pembrolizumab, an anti-programmed death cell protein 1 antibody, is successful in treating advanced head and neck squamous cell carcinoma, according to researchers from Fox Chase Cancer Center-Temple Health. This provides a new treatment option with fewer side effects. Presented at ASCO 2016 Annual Meeting.

PHILADELPHIA (May 19, 2016) — Researchers from Fox Chase Cancer Center and Temple University have developed a cellular programming approach that creates alloreactive T cells that are able to eliminate leukemic cells without causing graft versus host disease (GvHD).

PHILADELPHIA (May 4, 2016) — May is Skin Cancer Awareness Month, and chances are you will be spending more time outdoors. Fox Chase Cancer Center advises people to protect their skin from sun damage and become familiar with the early signs of skin cancer.

PHILADELPHIA (May 2, 2016) — Faculty, staff, volunteers, patients, survivors and their families and friends will come together as members of the Fox Chase Cancer Center–Temple Health team at AMP UP! Move to End Bladder Cancer’s annual 2-mile walk on Saturday, May 14, 2016.

PHILADELPHIA (May 1, 2016) — Many patients with breast or ovarian cancer initially benefit from DNA-damaging chemotherapies, but it has not been clear why these treatments lose effectiveness over time. In a new study, Fox Chase Cancer Center researchers showed that patients with mutations affecting a specific portion of the BRCA1 gene were susceptible to a new pathway of resistance to DNA-damaging drugs, including PARP inhibitors and platinum compounds.